Revolution Medicines, Inc. (NASDAQ: RVMD) reported Q3 EPS of ($0.94), $0.05 worse than the analyst estimate of ($0.89). Revenue for the quarter came in at $0 versus the consensus estimate of $807.69 thousand.

For earnings history and earnings-related data on Revolution Medicines, Inc. (RVMD) click here.